The population impact of human papillomavirus vaccination on cancer and pre-cancer outcomes: An umbrella review of meta-analyses.

TL;DR

HPV vaccination demonstrates 99% efficacy against HPV16/18 infection and 96% against CIN2+ in clinical trials, with observational data and ecological studies supporting substantial reductions in precancerous lesions and cervical cancer. Evidence quality is high for infection and warts but lower for invasive cancer prevention.

Key findings

• RCT efficacy: 99% against HPV16/18 infection, 96% against CIN2+, 89% against anogenital warts in HPV-naïve women
• Observational studies show relative risks of 0.12-0.36 for HPV16/18 and 0.48-0.68 for CIN2+; male effectiveness against warts 74-90%
• Ecological studies report 57-88% reductions in cervical cancer incidence across populations
• Evidence certainty: high for infection/warts and moderate for precancer; low for invasive cancer outcomes

Why this matters at the bedside

Provides population-level evidence synthesis supporting HPV vaccination effectiveness across infection, precancerous lesions, and cancer outcomes, with identified gaps in immunocompromised populations and long-term invasive cancer prevention data.